Hogan Lovells 2024 Election Impact and Congressional Outlook Report
Harmony develops and commercializes innovative therapies for patients with rare neurological diseases. Zynerba is a leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome (FXS), a rare genetic disorder that affects approximately 80,000 people in the U.S. causing intellectual disabilities and behavioral challenges.
Zynerba's lead asset, Zygel, is a pharmaceutically manufactured, synthetic cannabidiol, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. Zygel, currently in a pivotal Phase 3 clinical trial for the treatment FXS, is manufactured through a synthetic process and is not extracted from the cannabis plant.
The core Hogan Lovells team was led by partners William Intner (Baltimore, M&A and Securities) and Peter Cohen-Millstein (New York, M&A), with support from senior associate Shaida Mirmazaheri (Boston).
More information about the transaction is here.